Yale Engage Cancer Series: Presented by Corporate Strategy and Engagement Office, OCR, and Yale Cancer Center: "Defining Mechanisms and Biomarkers of Sensitivity & Resistance To Anti-Cancer Treatments"
In conjunction with Yale Cancer Center and the Office of Cooperative Research, the Corporate Strategy and Engagement office presents Yale Engage, an interactive webinar series promoting impactful collaboration between academic experts and industry executives. This is designed for a broad corporate audience, but particularly of interest for executives and leaders in Research & Development, Business Development, Strategy, and Innovation in sectors such as Biotechnology, Pharmaceutical, Healthcare, Technology, and Venture Capital. These sessions will feature corporate speakers with a panel of renowned Yale physicians and scientists addressing critical challenges.
With real-time dialogue and strategic introductions, we will pinpoint issues and research goals to advance shared, scalable solutions. In the fight against cancer, Yale Cancer Center is at the forefront of understanding the fundamental mechanisms of cancer biology and in developing effective cancer treatment therapies. The Cancer Center harnesses the resources of the Yale School of Medicine and Smilow Cancer Hospital at Yale New Haven to advance cancer research, prevention, and patient care, as well as community outreach and education.
Defining Mechanisms and Biomarkers of Sensitivity & Resistance To Anti-Cancer Treatments
The discussion will highlight mechanisms of resistance to clinical applications, developing and applying biomarkers, and drug sensitivity, as well as major challenges, such as:
- Identifying new targets for specific tumors
- Dissecting the complexity of drug resistance
- Reviewing systemic influences on tumors
- Pinpointing next gen biomarkers
Corporate Guest: Susan Galbraith, Senior Vice President and Head of Research and Early Development, Oncology R&D, AstraZeneca
AstraZenecaSusan GalbraithSenior Vice President and Head of Research and Early Development, Oncology R&D